The new date is Dec 21, 2021.
According to the Financial Times, Johnson & Johnson and Moderna are among the companies that are working with Oxford University to create a vaccine against the omicron coronaviruses variant.
A nurse is preparing a vaccine for a mass vaccine for the population between 60 and 65 years old. The photo was taken by Marcos del Mazo.
LightRocket is via a photo.
In a statement, the company said it has taken preliminary steps to create a variant-specific vaccine in case it is needed.
Sandy Douglas, leader of the Oxford University research group, told the Financial Times that adenoviruses-based vaccines could be used to respond to any new variant more rapidly.
Moderna and Johnson & Johnson have said they are researching vaccines that will specifically target the omicron variant, as Pfizer and Moderna claim their Covid-19 booster shots can successfully neutralize the virus.
Continue watching after the ad Visit Advertiser website.
On November 26th, the World Health Organization announced the discovery of the omicron variant in South Africa and a week later, the U.S. identified its first case. The variant has been reported in 48 states and has contributed to a Covid-19 case surge in multiple states. The spread of the omicron variant and rise in Covid-19 cases has prompted multiple cities to require proof of vaccine to enter certain indoor spaces.
There is a structure called the Tangent.
Last week, the company said that it had conducted studies that showed the effectiveness of the treatment. The FDA gave emergency use authorization for Evusheld in December to help prevent those who are immunocompromised from getting Covid-19.
Stephane Bancel, Moderna's Chief Executive Officer, said on Monday that the company would be ready to develop an omicron-targeted vaccine in a few weeks, and that it would be ready to begin trials for the vaccine in early 2022.
The Omicron-targeted vaccine will be produced by Oxford.
Omicron is the dominant covid variant in the US.
Oxford and AstraZeneca are working on a vaccine.
